Second Genome, Inc.

Genevive, Inc.

University of California

Todd Zachary DeSantis

Karim Dabbagh

Andrew Wonhee Han

Andrew Whitman Goodyear

Tarunmeet Gujral

Bernat Baeza Raja

Mitsuko Lynn Yamamoto

Shoko Kawana

Toshihiko Takeuchi

Gary L Andersen

Ye Jin

Stefanie Banas

Michi Izumi Willcoxon

Eoin L Brodie

Ulas Karaoz

Cheryl-Emiliane T Chow

Roberta L Hannibal

Jayamary Divya Ravichandar

Nicole R Narayan

Helena Kiefel

Kareem L Graham

Yuliya Katlinskaya

Sunit Jain

The disclosure related to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

Proteins for the treatment of epithelial barrier function disorders

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

The disclosure provides therapeutic peptides and pharmaceutical compositions comprising the peptides, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system to mitigate disease.

Microbially derived peptides and proteins for immunotherapy

Compositions, systems and methods for generating and using internal standard spike-in mixes including a combination of template spikes. Compositions, systems and methods described herein are directed to using the internal standard spike-in mixes to evaluate a set of workflow pipelines to perform differential abundance analyses on a sample containing variations of a target nucleic acid sequence of interest. Compositions, systems and methods described herein are directed to using the internal spike-in mixes to validate results obtained from differential abundance analyses performed on a sample containing variations of a target nucleic acid sequence of interest, where the variations may be of highly variable levels of relative abundance.

Methods for validation of microbiome sequence processing and differential abundance analyses via multiple bespoke spike-in mixtures

The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacteriumand their uses in treating metabolic-related diseases or disorder.

as a biotherapeutic

Herein is described methods for a high-sensitivity means to measure the incorporation of stable isotope labeled substrates into RNA following stable isotope probing experiments (SIP). RNA is hybridized to a set of probes such as phylogenetic microarrays and isotope incorporation is quantified such as by secondary ion mass spectrometer imaging (NanoSIMS).

Using phylogenetic probes for quantification of stable isotope labeling and microbial community analysis

Growing community of inventors

South San Francisco, CA, United States of America

Todd Zachary DeSantis